Palisade Bio begins MAD cohorts of Phase Ia/b ulcerative colitis therapy trial

US-based biopharmaceutical company Palisade Bio has begun the multiple ascending dose (MAD) cohorts of its ongoing Phase Ia/b trial of PALI-2108 for treating ulcerative colitis (UC).

These cohorts were launched following the completion of all five of the trial’s planned single ascending dose (SAD) cohorts.